Prospective study designed to evaluate the immunological effect of a specific strain of B. infantis on the incidence of atopic dermatitis, one of the most common pediatric allergic diseases.
DAVIS, California., February 15, 2023 /PRNewswire/ — Infinant Health, Inc, a company focused on improving infant health through the gut microbiome, today announced enrollment of the final participant in a study focused on the infant microbiome and immune health.
The study, which was carried out in finland by Johnson & Johnson Consumer Inc. in collaboration with Infinant Health, investigates the clinical and immunological effects of supplements with a live B. of the child strain in healthy breastfed infants at risk of developing atopic dermatitis (AD), one of the most common pediatric allergic diseases.
“Infinant Health is committed to improving the lifelong health of all babies through life-changing science and innovation to ensure all babies have a vital start in life,” said the CEO of Infinant Health. Mike Johnson. “Today, up to 20% of American children are affected by atopic dermatitis, usually the first manifestation of the ‘atopic march,’ a progression of allergic conditions, including food allergy. Studying the infant microbiome to inform potential solutions for This issue of immune health is critical as we aim to provide a healthier future for all children.”
The study enrolled over 270 infants in finland overcoming significant recruitment challenges associated with the pandemic and will assess the clinical and immunological outcomes of each subject over 2 years.
“As a prospective randomized placebo-controlled study, this is an important step toward proving the direct impact of B. of the child on the infant microbiome and its relationship to overall immune health,” said Infinant Health’s Global Medical and Scientific Advisor, Carl Sylvester.
To learn more about the study, visit the following link at ClinicalTrials.gov: A Study of a Probiotic Dietary Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis – Full Text View – ClinicalTrials.gov
ABOUT INFINANT HEALTH, INC
Infinant Health, Inc. (“Infinant Health”), formerly Evolve Biosystems, is a privately held company committed to changing the trajectory of human health by developing healthy immune systems through the infant microbiome. Infinant Health is building a product line to optimize infant health. Investors in the company include the Bill and Melinda Gates Foundation, Johnson & Johnson, Cargill and other leading institutions. Learn more about Infinant at www.infinitehealth.com.
Media contact: [email protected]
SOURCE Infinant Health
